Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that proper diagnosis and tailored long-term treatment can effectively manage androgenic disorders in women, improving patient care outcomes.

Exercise is crucial for managing polycystic ovary syndrome (PCOS) and improving overall health.

Exercise and finasteride together improve ovary health in PCOS rats.

High androgen levels in young women with PCOS are linked to higher blood pressure.

Dutasteride and finasteride do not significantly affect bone density, blood fats, or blood production, but slightly lower PSA levels and minimally impact sexual function in healthy young men.

Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.

Testosterone can help premenopausal and postmenopausal women with low sexual desire, but its long-term safety is unclear and it's not widely approved for this use.

Higher DKK-1 levels found in hair loss patients; L-ascorbic acid 2-phosphate, L-threonate, and ginsenoside F2 may help promote hair growth.

People with androgenic alopecia are more likely to have metabolic syndrome than healthy individuals.

Women with non-classic congenital adrenal hyperplasia have higher risk for heart and metabolic problems.

The document concludes that PCOS has a strong genetic component, but more research is needed to fully understand the specific genes involved.

Centratherum anthelminticum seed extract effectively treats Polycystic Ovary Syndrome in rats.

Finasteride effectively treats baldness but may cause sexual side effects.

High levels of testosterone and anti-Müllerian hormone before pregnancy are linked to a higher risk of newborns needing intensive care.

The new rodent model successfully mimics non-lean human PCOS symptoms.

Vitamin D deficiency is common in women with PCOS and linked to some metabolic problems, but not the main cause of their metabolic issues.

The review found no clear link between vitamin D receptor gene variations and polycystic ovary syndrome.

Gender-affirming hormone treatments need better patient-focused outcome measurements and standardized data collection.

Indian women with PCOS may need different ultrasound criteria for diagnosis than current standards.

Removing myelin protein zero-like 3 in mice leads to better metabolism and resistance to obesity.

Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.

Combination therapy with oral contraceptives and spironolactone improves hair growth, menstrual issues, and acne in women with PCOS.

More than half of the women with PCOS in Southern India had Metabolic Syndrome, with large waist circumference being the most common feature.

Metformin helps with menstrual cycles and insulin levels in PCOS but is less effective for hair growth, diabetes prevention, and weight loss, and may improve fertility and reduce diabetes risk.

Women with PCOS have similar levels of certain proteins compared to women without PCOS, and these proteins don't independently cause PCOS.

High levels of male hormones in women without tumors are linked to metabolic problems and can be treated with metformin.

The document concludes that accurate diagnosis of male and female gonadal disorders is crucial for effective treatment and better patient outcomes.

Insulin-sensitizing drugs like metformin can help with ovulation, weight loss, and lower testosterone in some women with PCOS.

Testosterone replacement may improve sexual desire and bone health in women with low androgen levels, but more research is needed on its long-term safety.

The document concludes that early recognition and treatment of PCOS in adolescents is crucial for managing symptoms and long-term health risks.